What's Happening?
Arrowhead Pharmaceuticals has presented new long-term data on the efficacy and safety of plozasiran, an investigational RNA interference therapeutic, at the American College of Cardiology’s 75th Annual Scientific Session. The study focused on patients
with severe hypertriglyceridemia (sHTG) and demonstrated an 83% median reduction in triglyceride levels, with 96% of patients achieving levels below 500 mg/dL, a threshold associated with increased risk of acute pancreatitis. The two-year open-label extension study showed no acute pancreatitis events among patients receiving plozasiran, reinforcing its potential as a therapeutic solution for hypertriglyceridemia. The study also reported favorable improvements in atherogenic lipoproteins and a consistent safety profile.
Why It's Important?
The results of this study are significant as they highlight plozasiran's potential to manage severe hypertriglyceridemia, a condition that significantly increases the risk of acute pancreatitis and cardiovascular diseases. The ability to reduce triglyceride levels effectively could lead to better management of these risks, improving patient outcomes. The study's findings also underscore the importance of targeting apolipoprotein C-III (APOC3) in triglyceride metabolism, offering a new approach to treating hypertriglyceridemia. This development could pave the way for more effective treatments for patients with limited options, addressing a significant unmet medical need.
What's Next?
Arrowhead Pharmaceuticals plans to complete ongoing Phase 3 clinical studies, including SHASTA-3, SHASTA-4, and MUIR-3, to support regulatory submissions for plozasiran's approval for severe hypertriglyceridemia. The company intends to submit a supplemental New Drug Application to the U.S. FDA by the end of 2026. If approved, plozasiran could become a key therapy for managing hypertriglyceridemia, potentially expanding its use to other cardiometabolic disorders. The continued success of plozasiran could also bolster Arrowhead's position in the RNA interference therapeutic market, showcasing the potential of their TRiM™ platform.
